#1 Clinical Trials Search in Europe

AZD1163

Clinical trials are investigating AZD1163 in adults with moderately to severely active rheumatoid arthritis. The main goal is to check whether it can improve symptoms and inflammation, and to assess safety and clinical efficacy compared with placebo.

Table of contents

Trial overview

The available study is an interventional study, which means researchers give a study treatment and then measure the results.[1] It is investigating AZD1163 in adults with rheumatoid arthritis that is moderately to severely active.[1] The trial is Phase 2 and has a planned enrollment of 295 participants.[1]

Who can participate

This study is designed for adult participants with rheumatoid arthritis.[1] The title says the condition must be moderately to severely active, which means the disease is causing a meaningful level of symptoms and inflammation.[1] The trial data do not list more detailed entry rules, so the exact participation criteria are not provided here.[1]

Study design and treatment groups

The study compares AZD1163 with placebo, which is a look-alike treatment used for comparison.[1] The intervention is listed as AZD1163 given by subcutaneous use, meaning it is administered as an injection under the skin.[1] The brief summary says the goal is to evaluate the clinical efficacy of AZD1163 compared with placebo.[1]

What the study measures

The main endpoint is the change from baseline in Disease Activity Score-C-Reactive Protein (DAS28-CRP) at Week 12.[1] Baseline means the starting point before treatment begins.[1] DAS28-CRP is a score used to show how active rheumatoid arthritis is, so changes in this score help show whether the study treatment is helping.[1]

What the results may mean

This trial is focused on whether AZD1163 can improve symptoms and inflammation in people with active rheumatoid arthritis.[1] Because it is a Phase 2 study, the results may help researchers learn more about both benefit and safety before larger studies are done.[1] The study status is listed as Authorised, which means it has been approved to move forward in the trial process.[1]

Trial ID Phase Condition studied Status Enrollment Main endpoint
2025-522076-85-00 Phase 2 Rheumatoid arthritis Authorised 295 Change from baseline in DAS28-CRP at Week 12

FAQ

  • What is being studied in AZD1163 clinical trials? The trial is studying AZD1163 in adults with moderately to severely active rheumatoid arthritis. It compares AZD1163 with placebo to see whether it improves symptoms and inflammation.
  • Who can take part in the AZD1163 study? Adults with moderately to severely active rheumatoid arthritis may be eligible. The trial is designed for people with this condition, but final participation depends on the study rules.
  • What phase is the AZD1163 trial? The trial is a Phase 2 study. Phase 2 trials usually look more closely at whether a treatment works and continue to assess safety.
  • What is the main result the study is measuring? The main endpoint is the change in Disease Activity Score-C-Reactive Protein, also called DAS28-CRP, at Week 12. This score helps show how active the rheumatoid arthritis is.
  • How many people are planned for the AZD1163 trial? The planned enrollment is 295 participants. This means the study aims to include 295 people.

Ongoing Clinical Trials on AZD1163

  • A study to evaluate the effectiveness and safety of AZD1163 in adults with moderate to severe rheumatoid arthritis

    Not yet recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Germany Hungary Poland Spain

Glossary

  • Rheumatoid arthritis: A long-term disease where the body's immune system attacks the joints, causing pain, swelling, and stiffness.
  • Moderately to severely active: This means the disease is causing a noticeable to strong level of symptoms and inflammation.
  • Inflammation: Swelling and irritation in the body. In rheumatoid arthritis, inflammation often affects the joints.
  • Placebo: A treatment that looks like the study drug but does not contain the active study medicine. It is used for comparison.
  • Phase 2: A stage of clinical research that looks at whether a treatment may work and continues to check safety.
  • Interventional study: A study where researchers give a treatment to participants and measure the results.
  • Subcutaneous use: Given under the skin as an injection.
  • Disease Activity Score-C-Reactive Protein (DAS28-CRP): A score used to measure how active rheumatoid arthritis is. Lower or changing scores can show improvement.
  • Baseline: The starting point before treatment begins.
  • Week 12: The time point 12 weeks after the study starts, when the main result is measured.
  • Clinical efficacy: How well a treatment works in a real study setting.

References

  1. https://clinicaltrials.gov/study/2025-522076-85-00